QL1706 (Iparomlimab and Tuvonralimab Injection): A Pioneering PD-1/CTLA-4 Bispecific Combination Antibody Showcased at 'Precision Strike, Enhanced Protection' Immuno-Oncology Innovation Symposium

Dialogue Keyword 1: "First-of-its-kind"

Academician Jinming YuStarting from the overall landscape of tumor immunotherapy, the innovative value of the Aituo combination antibody and the development direction of China's innovation are analyzed. He pointed out that the Aituo combination antibody, as the world's first PD-1/CTLA-4 combination antibody, adopts the innovative MabPair technology.^®Technical Platform Achieves the Golden Ratio of 2:1 for Two Antibodies, Enhancing Efficacy While Reducing Toxicity, Showing Potential in Multiple Indication Explorations. Meanwhile, Academician Yu also pointed out that Chinese scholars are increasingly becoming important participants on the international oncology academic stage. In recent years, multiple research achievements of the Aito combination antibody have been selected for top international academic conferences such as ASCO and ESMO, showcasing China's innovative strength in the field of tumor immunotherapy and contributing Chinese wisdom to the global advancement of cancer treatment, earning a good reputation internationally. As tumor immunotherapy enters a new era, innovative pharmaceutical companies in China are actively promoting the construction of new models for cancer treatment, bringing new hope for cancer patients.

Professor Ruihua XuProspects of Immunotherapy in Colorectal Cancer Were Explored. He pointed out that the layout of Aituo combination antibody in the field of colorectal cancer covers first-line treatment for advanced stages and perioperative treatment. This comprehensive research and development strategy has greatly driven exploration and innovation in this field. According to Phase II research data, first-line monotherapy with Aituo combination antibody in MSI-high colorectal cancer patients achieved an ORR of 62.5% and a DCR of 100%. The combination regimen showed a high ORR and good tolerability in first-line treatment of MSS/MSI-low colorectal cancer patients. Thus, through the synergistic effect of dual immune targets, Aituo combination antibody is expected to break through existing treatment bottlenecks and bring benefits to more patients.

Professor Zhou QiBased on the preliminary research data of the Aito combination antibody, its revolutionary significance for cervical cancer treatment is highlighted. For second-line and above treatment of recurrent or metastatic cervical cancer, this drug as a monotherapy demonstrates controllable safety and initial efficacy, offering benefits regardless of PD-L1 positivity or negativity. In first-line cervical cancer treatment, it has the potential to reshape the treatment landscape. In terms of safety, the incidence of adverse events with the Aito combination antibody is relatively low, clinically manageable, and associated with better patient tolerance. If subsequent studies further confirm survival benefits, this drug is expected to become a core option for immunotherapy in cervical cancer, potentially driving adjustments in current clinical practice to allow more patients to benefit from immunotherapy.

Professor Huang YanAs the principal investigator of DUBHE-L-303, she conducted an in-depth analysis of the clinical value and optimal benefit population of the Aito combination antibody. In the population resistant to EGFR-TKI, the combination therapy regimen of Aito achieved an ORR of 54.8%, a median PFS of 8.5 months, and a median OS of 26.5 months, providing a new treatment option for relatively refractory resistant patients. She particularly pointed out that the Phase III head-to-head study targeting EGFR/ALK-negative advanced first-line PD-L1 negative population has completed enrollment. This study is expected to address the clinical challenge of limited efficacy of immunotherapy in PD-L1 negative patients.

Dialogue Keyword 3: "Safety"

Professor Runxiang YangThe in-depth management experience of patients enrolled from their own center has affirmed the excellent safety of the Aituo combination antibody. Although immune checkpoint inhibitors have transformed the landscape of cancer treatment, monotherapy still faces challenges such as limited response rates and drug resistance. Previous studies suggest that combining two immune monoclonal antibodies enhances efficacy but also increases toxic reactions, significantly affecting patient compliance and prognosis. Professor Yang specifically noted that none of the 44 patients enrolled at Yunnan Cancer Hospital in the DUBHE-L-304 study experienced immune-related adverse events such as immune-related pneumonia or immune-related myocarditis, consistent with the results of the Phase I clinical study covering multiple tumor types.(The study enrolled 518 patients, with an incidence of grade ≥3 immune-related adverse events at only 8.1%), demonstrating good safety characteristics while enhancing anti-tumor activity.